Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2016-04-28 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
公司了解新疆爱迪新能源科技有限公司煤焦油加氢制备清洁燃料油项目终止涉及的部分资产价值评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an asset valuation report related to the termination of a specific project by Xinjiang Aidi New Energy Technology Co., Ltd. It contains detailed sections typical of an asset appraisal report, including the purpose of the appraisal, scope, valuation methods, assumptions, and conclusions. The report includes financial data on asset values, impairment, and detailed descriptions of the assets evaluated. It is prepared by a professional asset appraisal firm and includes certifications by registered asset appraisers. The document is not a general financial report, earnings release, or management discussion but a specialized valuation report focused on asset value assessment for a terminated project. This fits the definition of an Audit Report / Information (AR), which includes standalone audit or valuation reports and applied accounting principles. The document is substantive and lengthy (15,000 characters), not a mere announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is AR with high confidence. Q4 2015
2016-04-28 Chinese
2015年度财务决算报告
Annual Report Classification · 95% confidence The document is titled as a 2015 annual financial settlement report for 江苏四环生物股份有限公司, containing detailed financial data such as revenue, net profit, asset composition, expenses, cash flow, and cost structure for the year 2015 compared to previous years. It includes comprehensive financial statements and analysis, typical of an annual report. The document length is 5892 characters, which is sufficient to contain substantive financial data rather than just an announcement. There is no indication that this is a certification, announcement, or presentation. Therefore, this document fits the definition of an Annual Report (10-K). FY 2015
2016-04-28 Chinese
监事会关于公司2015年度内部控制自我评价的审议意见
Audit Report / Information Classification · 90% confidence The document is a supervisory board's opinion on the company's 2015 internal control self-evaluation report. It references the internal control evaluation report but does not contain the full report or detailed financial data. The document is short (304 characters) and serves as an audit or review opinion rather than a full annual report or audit report. It aligns best with an Audit Report / Information (AR) category, as it is a standalone audit-related statement about internal controls. FY 2015
2016-04-28 Chinese
监事会关于董事会对带强调事项段无保留意见审计报告的专项说明的意见
Audit Report / Information Classification · 95% confidence The document is a statement from the Supervisory Board regarding the auditor's report with an emphasis paragraph (a type of audit report). It references the auditor's unqualified opinion with emphasis of matter for the 2015 financial report and discusses compliance with regulatory disclosure rules. The document is not the full audit report itself but a supervisory board opinion on the audit report and related disclosures. It is not an annual report or financial statement but a standalone audit-related statement. Therefore, it fits best under Audit Report / Information (AR). The document length is short but contains substantive content related to audit opinion and regulatory compliance, not merely an announcement or certification. FY 2015
2016-04-28 Chinese
2015年度独立董事述职报告（徐小娟）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report" for the year 2015 from Jiangsu Sihuan Bio Co., Ltd. It details the independent director's activities, attendance at board and shareholder meetings, opinions on various board resolutions, and efforts to protect investor rights. The content focuses on governance and the independent director's role rather than financial results or audit opinions. It is not a full annual report, audit report, or earnings release. It is a management or board-related report describing director duties and opinions. Therefore, it fits best under Board/Management Information (MANG). The document length is short and does not contain financial statements or detailed financial data, so it is not an Annual Report or Interim Report. No indication of a meeting presentation or voting results is present, so AGM-R or DVA are not appropriate. Hence, the classification is MANG with high confidence.
2016-04-28 Chinese
2015年度独立董事述职报告（卢青）
Audit Report / Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2015 from Jiangsu Sihuan Bio Co., Ltd. It details the independent director's activities, attendance at board and shareholder meetings, opinions on various board resolutions, participation in audit work, and efforts to protect investor rights. The content is a narrative report on the independent director's duties and opinions rather than a full audit report or annual report. It does not contain financial statements or detailed audit results but rather the independent director's summary and opinions on company governance and audit participation. This type of document is best classified as a standalone Audit Report / Information (AR) because it relates to audit opinions and oversight without being the full annual report or audit opinion letter itself. The document length is short (1651 characters), and it is not merely an announcement or certification but a substantive report by the independent director on audit and governance matters. FY 2015
2016-04-28 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.